Clinical trial · Interventional
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ. Up to now, the prognosis of recurrent gliomas is very pessimistic and the standard treatment procedure has not been established yet. The prospective,multicentre phase II clinical study is to evaluate the efficacy and safety of TMZ and CDDP in patients with recurrent malignant gliomas
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Gliomas | Glioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TMZ | Drug | Temozolomide | ALIAS |
| TMZ plus CDDP | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- TMZ group
- description
- patients were treated with TMZ alone
- interventionNames
- Drug: TMZ
- type
- EXPERIMENTAL
- label
- TMZ plus CDDP group
- description
- patients were treated with TMZ plus CDDP
- interventionNames
- Drug: TMZ plus CDDP
Primary outcomes (1)
- measure
- over all survival
- timeFrame
- 1 year
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent * Age\>=18 and \<=70years old * Histological diagnosis of malignant gliomas(WHO III or IV) * The status of methylation of promotor of MGMT should be detected. * The time to be enrolled should be more than 90 days after the irradiation. * The patients with recurrent gliomas were treated with non-dose-dense TMZ therapy before enrollment. * Performance status(Karnofsky index)\>=60 * Life expectancy more than 3 months Exclusion Criteria: * Ages:\< 18 years or \> 70 years * Abnormal function of liver or renal(value more than 1.5 fold normal upper limit ) * Blood routing: Hb \< 100g/l， WBC \< 4.0×109/l; PLT \< 100×109/l * Pregnant or lactating women * Allergic to administered drugs * Radiation treatment in the previous 90 days or stereotactic radiation surgery within 60 days before enrollment * The patients with recurrent gliomas were treated with dose-dense TMZ therapy before enrollment. * Life expectancy less than 3 months * Participation in other clinical trials in the 90previous days before enrollment
References
Publications (0)
Data not yet available